ABBV-8736 Safety and Tolerability in Healthy Adults
ABBV-8736
+ Placebo
Basic Science Study
Summary
Study start date: September 2, 2025
Actual date on which the first participant was enrolled.This study aims to explore how a new drug called ABBV-8736 behaves in the body and how the immune system responds to it. It is conducted with healthy adults to ensure the safety of the drug before it is tested in patients with specific conditions. This research is crucial in determining the initial safety and appropriate dosage levels, which is a foundational step in the development of new medications that may eventually help treat various diseases. Participants in this study receive the drug ABBV-8736 through an intravenous (IV) method, which means it is administered directly into the bloodstream. The study examines different doses to see how well participants tolerate the drug and to check for any adverse effects. The effects of the drug are closely monitored, including how it is processed by the body and whether it triggers any immune response. This data helps researchers understand the potential risks and benefits, laying the groundwork for future studies with patients who may benefit from the medication.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.24 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Basic Science Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 55 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Inclusion Criteria: * Body mass index (BMI) is \>= 18.0 to \<= 32.0 kg/m\^2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG. Exclusion Criteria: * History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness. * History of any clinically significant sensitivity or allergy to any medication or food. * Prior exposure to a TREM1 agent.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.4 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
ExperimentalGroup III
PlaceboGroup IV
PlaceboStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location